Predictors of Radiological and Clinical Disease Reactivation in Multiple Sclerosis Patients After Cessation of Natalizumab (Tysabri)
Brain and Behavior · 2025
DOI: 10.1002/brb3.70904 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain and Behavior, 2025. Verfasst von Roba El Zibaoui und 2 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, American University of Beirut, Beirut, Lebanon. Hauptthemen laut MEDLINE: Natalizumab, Multiple Sclerosis, Relapsing-Remitting, Immunologic Factors. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background and Purpose : Natalizumab (NTZ) is widely used for patients with highly active relapsing–remitting multiple sclerosis (RRMS), but its discontinuation can lead to disease reactivation, significantly impacting Middle Eastern populations. This study aimed to assess the frequency of disease reactivation post‐NTZ discontinuation and identify possible demographic predictors.
Methods
In this retrospective single‐center study, 171 patients with RRMS who received at least six consecutive NTZ infusions were analyzed. Clinical and radiological data were sourced from the AMIR registry. Binary and multivariate regression analyses were performed to identify factors associated with reactivation risk after 1 year, with a subset undergoing brain magnetic resonance imaging (MRI) segmentation and volumetric assessments.
Results
Among 92 eligible patients, 16 (17%) showed disease reactivation. Prolonged washout periods (>3 months) significantly increased reactivation risk (hazard ratio [HR] 1.015, 95% CI 1.007–1.022, p < 0.001), whereas higher Expanded Disability Status Scale (EDSS) scores correlated with a reduced risk (HR 0.492, 95% CI 0.280–0.866, p < 0.014). In the subset of cases that underwent brain MRI segmentation, higher NTZ infusion numbers and delayed bridging therapy initiation were linked to increased reactivation risk.
Conclusion
NTZ discontinuation requires thorough clinical evaluation for bridging therapy, yet optimal strategies remain undefined. Early bridging therapy initiation may mitigate reactivation, highlighting the need for further research on predictive factors and disease‐modifying therapy efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine, American University of Beirut, Beirut, Lebanon.
- Department of Neurology, American University of Beirut Medical Center, Beirut, Lebanon.
- Nehme and Therese Tohme Multiple Sclerosis Center, American University of Beirut Medical Center, Beirut, Lebanon.
ORCID-Profile: Roba El Zibaoui, Nabil K El Ayoubi, Samia J Khoury
Zitieren
APA
Zibaoui, R. E., Ayoubi, N. K. E., & Khoury, S. J. (2025). Predictors of Radiological and Clinical Disease Reactivation in Multiple Sclerosis Patients After Cessation of Natalizumab (Tysabri). Brain and Behavior. https://doi.org/10.1002/brb3.70904
Vancouver
Zibaoui RE, Ayoubi NKE, Khoury SJ. Predictors of Radiological and Clinical Disease Reactivation in Multiple Sclerosis Patients After Cessation of Natalizumab (Tysabri). Brain and Behavior. 2025. doi:10.1002/brb3.70904
BibTeX
@article{Zibaoui2025,
author = {Zibaoui, Roba El and Ayoubi, Nabil K El and Khoury, Samia J},
title = {Predictors of Radiological and Clinical Disease Reactivation in Multiple Sclerosis Patients After Cessation of Natalizumab (Tysabri)},
journal = {Brain and Behavior},
year = {2025},
doi = {10.1002/brb3.70904}
}
EUVIMED